Tasquinimod
- Generic Name
- Tasquinimod
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C20H17F3N2O4
- CAS Number
- 254964-60-8
- Unique Ingredient Identifier
- 756U07KN1R
- Background
The quinoline-3-carboxamide anti-angiogenic agent, tasquinimod, enhances the anti-prostate cancer efficacy of androgen ablation and taxotere without effecting serum PSA directly in human xenografts
- Indication
Investigated for use/treatment in prostate cancer.
- Associated Conditions
- -
- Associated Therapies
- -
Active Biotech reduces loss slightly - projects progressing according to plan
Active Biotech reported no sales in Q4, with a slight decrease in operating loss. CEO Helén Tuvesson highlights positive progress in clinical projects for tasquinimod and laquinimod. The company looks forward to 2023 with a strong clinical focus and financial position to meet planned milestones.
Active Biotech's preclinical data on tasquinimod presented at ASH
Active Biotech's preclinical data on tasquinimod in treating myelofibrosis accepted for ASH 2024 poster presentation, suggesting potential broad effects as monotherapy and combination treatment.
Active Biotech's tasquinimod study receives green light from EMA
Active Biotech's Phase I/II trial of tasquinimod for myelofibrosis patients refractory or intolerant to JAK2 inhibition receives full approval from EMA and ethics committees. The open-label, multicenter study will assess tasquinimod's safety and efficacy as monotherapy.
Active Biotech's clinical trial of tasquinimod in myelofibrosis approved in Europe
Active Biotech's phase I/II study of tasquinimod for myelofibrosis patients refractory to or intolerant of JAK2 inhibition (HOVON 172 MF) has received full approval from the EMA and ethics committees. The study will evaluate tasquinimod's safety and efficacy as monotherapy, with a primary endpoint of a 35% reduction in spleen volume after six cycles. Conducted by HOVON in the Netherlands and Germany, Oncode Institute is the main financier.
Related Clinical Trials:
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath